Breast cancer patients can be classified into diverse patient subgroups with different prognosis and treatment response according to their classical clinicopathological and molecular features, such as estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) [2]. This evidence concerns the gene ESR1 and breast cancer.